LEXICON PHARMACEUTICALS, INC.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
LXRX$1.82+2.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. · Description | ||
|---|---|---|
| *†10.1 | — | Exclusive License Agreement, dated March 27, 2025, with Novo Nordisk A/S |
| †10.2 | — | Seventh Amendment to Loan and Security Agreement, dated March 27, 2025, with Oxford Finance, LLC and the lenders listed therein (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated March 27, 2025 and incorporated by reference herein). |
| *31.1 | — | Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| *31.2 | — | Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| *32.1 | — | Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS | — | XBRL Instance Document |
| 101.SCH | — | XBRL Taxonomy Extension Schema Document |
| 101.CAL | — | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | — | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | — | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | — | XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | — | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| * | Filed herewith. |
|---|---|
| † | Certain information (indicated by “[**]”) has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the Company if publicly disclosed. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.